# DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

> **NCT04967482** · NA · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 216 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** Drug-eluting bead transarterial chemoembolization (DEB-TACE)
- **PROCEDURE:** Conventional transarterial chemoembolization (cTACE)

## Key facts

- **NCT ID:** NCT04967482
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-07-08
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967482, "DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04967482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*